AOD-9604 was studied in human clinical trials for obesity treatment in the early 2000s. While early Phase II trials showed some promising signals for body composition changes, Phase III trials were not completed, and the compound did not receive FDA approval as an anti-obesity drug. It holds FDA GRAS (Generally Recognized As Safe) status for use in food, which is sometimes cited in marketing materials — though this is a different standard than drug approval.
AOD-9604 is currently available as a compounded peptide through licensed providers. It is typically administered via subcutaneous injection. The clinical evidence base is smaller than for approved medications, and patients should have realistic expectations and work closely with a physician who can track progress and adjust accordingly.
and are almost always used together and are among the most popular peptides in the body composition space. Understanding each.
Together, they work synergistically to produce a more robust and sustained release of growth hormone than either would alone.
Growth hormone plays a central role in body composition. It promotes.
Many patients using / report improved body composition over several months — specifically, a gradual shift toward less fat mass and more lean muscle — even without dramatic changes in weight on the scale. This makes it particularly useful for patients who want to look and feel leaner while preserving muscle during a calorie deficit.
/ is typically administered via subcutaneous injection before bed (to align with the body's natural GH pulsatility during sleep). Some protocols also include a morning injection. Results typically develop over 3–6 months of consistent use.
5-Amino-1MQ is a small molecule compound (technically a methylquinolinium compound rather than a traditional peptide, though it is often grouped with peptide therapies) that works as an inhibitor of an enzyme called NNMT (nicotinamide N-methyltransferase).
NNMT is an enzyme found primarily in fat tissue that plays a role in regulating fat cell metabolism. When NNMT is overactive — as it tends to be in obesity and metabolic disease — it promotes a state in which fat cells are more efficient at storing energy and less responsive to lipolysis signals.
Studies suggest that inhibiting NNMT with compounds like 5-Amino-1MQ may.
The research on 5-Amino-1MQ is still early-stage, primarily from animal studies, with human data limited. It is available as a compounded oral capsule. Patients interested in this compound should understand the current evidence limitations and discuss them with a knowledgeable physician.
If you're comparing peptides to GLP-1 medications for weight lossit helps to think of them as tools that work through fundamentally different mechanisms.
| Factor | GLP-1 Medications (Semaglutide/Tirzepatide) | Body Composition Peptides (/AOD-9604) |
|---|---|---|
| Primary mechanism | Appetite suppression, slowed gastric emptying | GH stimulation, direct fat metabolism effects |
| Weight loss magnitude | 15–25% of body weight (clinical trials) | Modest (varies, often 5–10 lbs body composition goals over months) |
| Muscle preservation | Some concern about muscle loss during rapid weight loss | May actively support muscle preservation and gain |
| Best for | Significant weight reduction, metabolic disease | Body recomposition, preserving lean mass, adjunct support |
| FDA approval status | FDA-approved for obesity/diabetes | Not FDA-approved (compounded) |
One of the areas where peptides may offer the most value is as part of a combined strategy.
Any combination approach should be supervised by a licensed provider who can monitor for interactions and adjust protocols based on response. Explore our full peptide therapy page for more details on available options.
It's important to have realistic expectations when starting peptide therapy for body composition goals.
If your primary goal is significant weight reduction (e.g., losing 30+ pounds), GLP-1 medications are likely to be a more central part of your treatment plan, with peptides potentially serving as a complementary element.
Truventa Medical's licensed providers can evaluate your goals and help design a personalized approach to body composition optimization.
Get Started TodaySeveral peptides are used in the context of weight management and body composition improvement. Commonly discussed options include AOD-9604 (a fragment of growth hormone thought to influence fat metabolism), and (growth hormone-releasing peptides that may increase lean mass and support body composition goals), and 5-Amino-1MQ (which targets an enzyme involved in fat cell metabolism). These are typically compounded peptides prescribed by physicians and not FDA-approved as weight loss drugs.
GLP-1 medications like semaglutide and tirzepatide generally produce more significant weight loss (15–25% of body weight in clinical trials) compared to peptides like AOD-9604 or /. Peptides are often considered complementary tools — particularly for optimizing body composition (preserving or building muscle while reducing fat) — rather than primary weight loss treatments.
AOD-9604 is not FDA-approved as a drug for any indication. It is available as a compounded peptide through licensed providers and compounding pharmacies. Patients considering AOD-9604 should work with a licensed provider who can evaluate appropriateness, discuss the current evidence, and monitor for any adverse effects.
This peptide is a growth hormone-releasing hormone (GHRH) analog, and is a growth hormone secretagogue. Together, they stimulate the pituitary gland to release more growth hormone. Elevated growth hormone levels support increased muscle protein synthesis, improved fat metabolism (lipolysis), and better recovery from exercise. The body composition changes — more lean mass, less fat — are a byproduct of optimized growth hormone levels.
Some physicians do use combination approaches — for example, using a GLP-1 medication for appetite suppression and overall weight loss while using peptides like / to preserve or build lean muscle mass during the weight loss process. Combining approaches should always be done under physician supervision with appropriate monitoring.
Most weight loss peptides are administered via subcutaneous injection (small needle under the skin), typically daily or several times per week. Some peptides are available in oral or nasal spray forms, though these routes have reduced bioavailability compared to injections. Your provider will guide you on proper injection technique and dosing schedules.